First plagiarism, now manipulation of science studies data

[limblips]

Harvard, where the future democrats learn their trades.

Dana-Farber to Retract 6 Papers, Correct 31 Following Data Manipulation Claims | News | The Harvard Crimson

The Dana-Farber Cancer Institute initiated retractions or corrections to 37 papers authored by four senior researchers following allegations of data falsification, according to a DFCI research integrity officer Sunday.

www.thecrimson.com

 

[GURPS]

30 yrs of data manipulation since the start of the climate emergency

 

[GURPS]

Harvard Medical “Expert” Disqualified in Federal Court Case Due to “Overwhelming” and “Misleading” Plagiarism​

Judge Dalton summed up:

In sum, the rampant plagiarism in Dr. Panigrahy’s report leads the Court to conclude that his general causation methodology as a whole is too unreliable to put before a jury. So Lockheed’s motion to exclude Dr. Panigrahy is due to be granted in full. With Dr. Panigrahy excluded, there is no reliable general causation testimony on any of the types of cancer at issue, so summary judgment is due to be granted in favor of Lockheed on the exposure claims of [22] Plaintiffs.

That means Lockheed wins the case, and these Plaintiffs’ claims against Lockheed are dismissed, with prejudice, meaning these claims may not be brought again in any court of law.

Dr. Panigrahy’s report was so bad that it made Nathan Schachtman’s Wall of Shame blog, who went over the Lockheed case, Dipak Panigrahy – Expert Witness & Putative Plagiarist, and then noted Dr. Panigrahy’s current job title:

The putative plagiarist, Dr. Panigraphy, is an assistant professor of pathology, at Harvard Medical School, in the department of pathology, Beth Israel Deaconess Medical Center, in Boston.

Schachtman also notes that Panigrahy had his opinion excluded in another federal court case in 2022:

Panigraphy has a profile at the “Expert Institute,” sort of an employment agency for expert witnesses. His opinions were excluded in the federal multi-district litigation concerning Zantac/ranitidine. In re Zantac (ranitidine) Prods. Liab. Litig., MDL NO. 2924 20-MD-2924, 644 F. Supp. 3d 1075, 1100 (S.D. Fla. 2022).

Looks like Harvard has more to clean up than just the DEI and President’s office. And, I might add, it’s one thing for the head of DEI to have plagiarized, it is quite another for Harvard Medical School professors to have plagiarized. Good lord.